164 Ann Thorac Surg 45: , Feb Copyright by The Society of Thoracic Surgeons
|
|
- Andra Simpson
- 6 years ago
- Views:
Transcription
1 Heart Valve Replacement with the Bjork-Shiley Mbnostrut Valve: Early Results of a Multicenter Clinical Investigation Lars I. Thulin, M.D., William H. Bain, F.R.C.S., Hans H. Huysmans, M.D., Gerrit van Ingen, M.D., Ignatio Prieto, F.R.C.S., Fadi Basile, F.R.C.S., Dan A. Lindblom, M.D., and Christian L. Olin, M.D. ABSTRACT To evaluate the clinical performance of the Bjork-Shiley Monostrut prosthesis, five centers combined their early experience. Between May, 982, and June, 985, 537 prostheses were implanted in 486 patients at these centers: 246 patients had aortic valve replacement (AVR), 63 underwent mitral valve replacement (MVR), and 47 had double-valve replacement (DVR). Thirty patients underwent other, more complex procedures. Concomitant cardiac procedures were performed in altogether 25%. Overall hospital (3 days) mortality was 5.% (3.6% for AVR, 4.3% for MVR, 8.3% for DVR, and 6.6% for other procedures). The patients were followed up at 6- to 9-month intervals from 6 to 48 months (mean follow-up, 33 months). Followup was 99.6% complete. Late mortality was 7.2%. The three-year survival rate was 9.% for AVR, 92.3% for MVR, and 76.2% for DVR. There was no structural failure of the prosthesis. No instances of valve thrombosis and fatal thromboembolism occurred in anticoagulated patients. The three-year incidence of freedom from thromboembolic events (including TIA) was 89.8% for AVR, 94.9% for MVR, and 9.2% for DVR. Preoperative and postoperative data for the assessment of mechanical hemolysis was available in 6% of the patients. The degree of mechanical hemolysis was low and did not change with time. Although the follow-up is still short, the Bjork- Shiley Monostrut prosthesis appears to represent an improvement over previous Bjork-Shiley models, particularly with regard to durability. Since the introduction of the Bjork-Shiley tilting disk valve in 969 [l], the prosthesis has undergone progressive development to improve its hemodynamic performance, diminish thromboembolic complications, and to increase its durability. In the latest model, the Bjork- Shiley Monostrut (Monostrut, Shiley, Irvine, California) prosthesis (8-S M), the outflow strut (as well as the inflow strut) has been made an integral part of the cage From the Departments of Cardiothoracic Surgery at Lund University Hospital, Lund, Sweden; Western Infirmary, Glasgow, Scotland; Academic Hospital, Leiden, Holland; HBpital Hotel-Dieu de Montreal, Quebec, Canada; and Karolinska Hospital, Stockholm, Sweden. Accepted for publication Aug 3, 987. Address reprint requests to Dr. Olin, Department of Thoracic Surgery, Lund University Hospital, S Lund, Sweden. [2]. The cage and the struts are machined from a single piece of Haynes 25, a cobalt-based alloy, by a special electromechanical process. The single outflow strut, the "Monostrut," is shaped like a hook and has a broad base to increase its strength (Fig ). The convexoconcave disk is made of pyrolytic carbon and opens to 7 degrees to decrease resistance to flow. Two types of suture rings are available, Teflon and carbon-coated Dacron. To get a sufficiently large patient sample to study, the early experience of five centers, four European and one Canadian, were combined into a multicenter investigation. Uniform methods of follow-up and definitions of complications were agreed on. Special attention was focused on valve-related complications such as mechanical failure, thromboembolism, and prosthesis-induced hemolysis. Patients and Methods The study group comprised 486 patients who underwent valve replacement with the B-S M prosthesis between May, 982, and June, 985, at the five centers: 246 had aortic valve replacement (AVR), 63 had mitral valve replacement (MVR), and 47 underwent doublevalve replacement (DVR). Thirty patients underwent uncommon or more complex procedures, for which another prosthesis (or prosthetic material) was implanted in addition to the B-S M prosthesis. A total of 54 B-S M prostheses were implanted: 39 in the aortic position, 223 in the mitral position, 7 in the tricuspid position, and in the pulmonic position. The B-S M prosthesis was used to replace a natural valve in 96% and a failed prosthesis in 4%. Concomitant cardiac procedures were performed in 25% of the patients, coronary artery bypass being the most common (Table ). Tricuspid valve repair was performed in 8% of those with MVR and in 6% of those with DVR. Preoperative patient characteristics are shown in Table 2. The mean age of the patients was 56.8 years (age range, 2-78 years). There was a male preponderance in the AVR group and a female preponderance in the MVR and DVR groups. The majority (72%) of the patients were in New York Heart Association (NYHA) Functional Class I and IV. Altogether, 9.% had undergone previous cardiac operations. Preoperative atrial fibrillation was present in 7.4% of the patients with AVR, 58.9% of those with MVR, and 44.7% of those with DVR. Preoperative thromboembolic episodes (TEs) were recorded in 5.2% of the patients. Ninety-five percent of 64 Ann Thorac Surg 45:64-7, Feb 988. Copyright 988 by The Society of Thoracic Surgeons
2 ~ ~~ ~~~ - 65 Thulin r:t al: Replacement with Bjork-Shiley Monostrut Valve cylic acid, were maintained postoperatively on a regimen of chronic anticoagulation therapy with warfarin sodium or dicumarol. The therapy was usually started on the second postoperative day. The 33 patients from the Karolinska Hospital suffered a higher rate of TE because they were not treated with dicumarol anticoagulation, but since the study pool consisted solely of consecutive patients from the five centers, they are included in the series. These patients have been described in detail ip a separate publication [3]. Fig. The Bjork-Shiley Monostrut prosthesis. Mitral version with Teflon suture ring. the operations were elective procedures, whereas the remaining S% were emergent procedures. Operative Technique Standard cardiopulmonary bypass technique, including cold cardioplegia for myocardial protection, was used at all centers. The technique for implantation of the B-S M prosthesis varied, but since there was no significant difference in the results, this aspect has not been detailed. Furthermore, some centers used the Teflon suture ring whereas others used the carbon-coated Dacron one. There was no difference in results with regard to the incidence of thromboembolic complications and periprosthetic leaks. Postoperative Management All patients, with the exception of 33 patients from the Karolinska Hospital, who initially received acetylsaji- Patient Follow-up All patients were followed up at 6- to 9-month intervals through hospital visits, telephone interviews, or special questionnaires. Follow-up time was defined as the time between operation apd the last active follow-up. The follow-up ranged between 6 and 48 months (mean followup, 33 months) and was available for 99.6% of the patients. Postoperative blood data for determination of mechanical hemolysis were available in 6% of the patients surviving beypnd 3 days. Because of differences in normal values for serum lactic dehydrogenase between laboratories, the percentage of upper normal Was used. Definition of Complicutions Complications were defined in the following manner: Early mortality: death within 3 days of operation. Valve throrpbosis: obstruction or interference of disk movement by thrgmbus, confirmed at reoperation or autopsy. Systemic embolism; any svdden blockage of the arterial circulatiqp to any organ, occurriqg after the patient had woken up after operation. Thus, cerebrovascular accidents occuqjng during operatian were not considerfd to be due to valve-related eqbolism. All other episodes of cerebral, coronary, or systemic infqrction were documented as emboli, upless proven to be due to some other cause. Embolic events 'were subdivided Table. Concomitant Cardiac Proceduresa Other AVR MVR DVR Proceduresb Procedure (N = 246) (N = 63) (N = 47) (N = 3) Total Coronary artery bypass 43 (7) 2 (2) 63) 69 Tricuspid valve repair 3 (8) 3 (6) 2 8 Mitral valve repair 3 4 Resection of LV aneurysm 2 2 Resection of ascending aortic aneurysm Insertion of permanent pacemaker 4 5 Miscellaneous procedures Total 54 (22) 4 (25) (23) 5 2 Tercentages are shown in parentheses. bimplantation of another prosthesis or prosthetic material in addition to the Bjork-Shiley Monostrut prosthesis. AVR = aortic valve replacement; MVR = mitral valve replacement; DVR = double-valye replacement; LV = left ventricular.
3 ~ ~ 66 The Annals of Thoracic Surgery Vol 45 No 2 February 988 Table 2. Preoperative Patient Characteristics Other AVR MVR DVR Procedures Total Variable (N = 246) (N = 63) (N = 47) (N = 3) (N = 486) Age (yr) Mean Range Sex Male Female NYHA Class I I IV Previous cardiac surgery (%) Previous valve replacement (%) Preop. atrial fibrillation (%) Preop. thromboembolic events (%) AVR = aortic valve replacement, MVR = mitral valve replacement, DVR = double-valve replacement, NYHA = New York Heart Associahon into transient ischemic attacks (TIAs), inferring complete recovery within 24 hours, and TEs. Anticoagulation bleeding: any internal or external bleeding severe enough to warrant hospitalization, blood transfusion, or nontrivial outpatient care. Prosthetic valve endocarditis: postoperative endocarditis occurring de novo confirmed by positive bacterial culture, reoperation, or postmortem examination. Periprosthetic leakage: any regurgitation occurring around the prosthesis confirmed by catheterization, by reoperation, or at autopsy. Hemolysis: any red blood cell destruction resulting in anemia in the absence of periprosthetic leakage or endocarditis. Mechanical failure: any intrinsic mechanical or structural failure. Disk interference: any impairment of the free movement of the disk not attributable to valve thrombosis or mechanical failure. Event-free survival: percentage of patients alive and free from any valve-related and anticoagulation-related complications. Statistical Analyses To estimate survival, incidence of freedom from valverelated complications, and event-free survival, the statistical method of Lee was used [4]. The Statistical Analysis System [5] was the base for all computations performed. Chi-square statistics were used to estimate differences between the groups. Differences resulting in a p value of less than.5 were considered significant. For analysis of late survival, patients lost to follow-up or later receiving a prosthesis other than the B-S M were withdrawn. For analysis of nonfatal events, the patients were with- drawn at the time of the first event or at the time of death. Results Early Mortality There were 25 early deaths (within 3 days of operation), resulting in an early mortality of 5.%. The early mortality was 3.6% for AVR, 4.3% for MVR, 8.3% for DVR, and 6.6% for other procedures. The causes of early deaths were as follows: Myocardial failure Myocardial infarction Bleeding Sepsis Cerebrovascular accident Pancreatitis Pneumonia Pulmonary embolism Valve thrombosis The most common cause of hospital mortality was myocardial failure. Factors associated with increased early mortality were concomitant major surgical procedure, NYHA Functional Class IV, and emergent operation. One patient died 29 days after operation because of valve thrombosis. This was a 56-year-old woman who had undergone aortic valve replacement. She belonged to the early series from the Karolinska Hospital and was discharged without dicumarol anticoagulation. Late Mortality There were 33 late deaths (later than 3 days), resulting in a late mortality of 7.2%. The causes of late deaths were as follows: 4 3 3
4 67 Thulin et al: Replacement with Bjork-Shiley Monostrut Valve Cardiac arrhythmia Cancer Bleeding Heart failure Myocardial infarction Sepsis Pseudomembranous colitis Postirradiation pneumonitis Aortic rupture Valve thrombosis Unknown m L m c a =MVR (92.3%) * =AVR (9.O%) \ \ --.A =DVR (76.2%) m AVR MVR DVR Cardiac arrhythmia and cancer were the most common causes of death. Four of the 5 late deaths attributed to bleeding were caused or aggravated by the anticoagulation therapy. There was no statistical correlation between preoperative patient characteristics and the occurrence of late death. One patient whose late death was due to valve thrombosis was a 59-year-old woman who had undergone isolated AVR. Although she was discharged on a regimen of anticoagulants, this therapy was stopped against the advice of the investigator. The patient died 6 months later, and valve thrombosis was confirmed at autopsy. Since the autopsy rate was not loo%, additional cases of valve thrombosis cannot be excluded among the patients dying late of cardiac arrhythmia or of unknown causes. The actuarial survival curves for the AVR, MVR, and DVR patients are shown in Figure 2. The three-year survival was 9.% for the AVR patients, 92.3% for the MVR patients, and 76.2% for the DVR patients. The relatively low survival at three years for DVR (76.2%) is due to a few deaths in the small group of patients followed up to 3 years. They were all in NYHA Functional Class I and IV, and they all had stenotic disease. Thromboembolism Altogether, 3 patients suffered from TEs (including TIA). Most emboli were small and left the patients without residual symptoms. No event was fatal. The linearized TE rate (including TIA) was 3.4%/patient-year for AVR, 5.%/patient-year for MVR, and 2.7%/patient-year for DVR. The actuarial incidence of freedom from TE events (including TIA) is shown in Figure 3. At 3 years, 89.8% of the AVR patients, 94.9% of the MVR patients, and 9.2% of the DVR patients were free from TE complications (including TIA). The low figure for the AVR group was adversely influenced by the higher rate of TEs in the early AVR series from the Karolinska Hospital, where anticoagulants were not used. These patients have been described in detail in a separate publication [3]. Among these 33 patients there were 2 cases of fatal valve thrombosis (as mentioned earlier) and 3 cases of systemic emboli. No statistical correlation was found between the incidence of TE and preoperative risk factors such as old age, high NYHA class, preoperative atrial fibrillation, and preoperative TE events. Fig 2. Actuarial survival after heart valve replacement with Bjork- Shiley Monostrut prostheses. The downward trend of the double-valve replacement (DVR) curve might be explained by the few deaths in the small group of DVR patients observed beyond 24 months. (AVR = aortic valve replacement; MVR = mitral valve replacement.) - 9 I- I- -. =DVR (9.2%...+ =AVR (9.8%.--A LMVR (94.9%) AVR MVR DVR 5 I,, I I I c Time after surgery (months) Fig 3. Actuarial incidence offreedom from thromboembolism (including transient ischemic attacks; TIA) after heart valve replacement with Bjiirk-Shiley Monostrut prostheses. (DVR = double-valve replacement; AVR = aortic valve replacement; MVR = mitral valve replacement.) An ticoagulation-related Bleeding Altogether, 23 patients suffered from bleeding episodes potentially related to the anticoagulation therapy. Four (7%) of the episodes were fatal. The actuarial curve for freedom from anticoagulation-related bleeding is shown in Figure 4. At 3 years, 9.6% in the AVR group, 96.2% in the MVR group, and 87.% in the DVR group were free from this affliction. There was also no correlation to the preoperative risk factors in this category. Peripros t hetic Leakage Paravalvular leakage was seen in patients (2%). Six patients underwent reoperation, and mechanical hemolysis was seen in 3 of them. Prosthetic Valve Endocarditis Postoperative endocarditis developed in 7 patients. All underwent reoperation, and 2 patients died. Reoperations were performed between 3 and 28 months postoperatively (mean time, 9 months).
5 68 The Annals of Thoracic Surgery Vol 45 No 2 February =MVR (96.2%) -... =AVR (9.6%) ---A=DVR (87.%) ' I I AVR MVR DVR Time after surgery (months) Fig 4. Actuarial incidence of freedom from anticoagulation-related bleeding with Bjork-Shiley Monostrut prostheses. (MVR = mitral value replacement; AVR = aortic valve replacement; DVR = doublevalue replacement.) Mechanical Failure No mechanical failures were observed. Autopsy was performed in two thirds of the patients who died. Valve failure was not suspected clinically in the remaining patients. Disk lnterference Two patients with MVR underwent reoperation for relief of disk interference. In both patients the disk impinged against the left ventricular wall, possibly because too large a valve had been chosen in relation to the left ventricular size. In both patients acute reoperation with reorientation of the valve was performed. One patient, who also had to be reoperated on twice because of bleeding, subsequently died. The other patient was asymptomatic but continued to have disk interference radiographically (disk opening angle reduced to 45-6 degrees). Interestingly, at a follow-up investigation 22 months after operation, when the heart rhythm had reverted from atrial fibrillation to sinus rhythm, the disk impingement had disappeared and the disk opened to the expected 7 degrees at all heartbeats. Hemolysis Four patients had evidence of increased mechanical hemolysis. In 3 patients the hemolysis was associated with a periprosthetic leak. The fourth patient was the first patient described in the preceding section who was reoperated on three times. She received numerous blood transfusions and subsequently suffered from liver insufficiency and hepatitis. In 295 patients surviving beyond 3 days, preoperative and postoperative blood data to assess the degree of prosthesis-induced hemolysis were available (Table 3). With the exception of the 4 patients mentioned in the preceding section, all patients had normal postoperative hemoglobin values. In fact, most patients had a higher hemoglobin value after operation than before operation. Serum lactic dehydrogenase activity and reticulocyte count were only slightly elevated postoperatively, indicating that the degree of mechanical hemolysis was low and clinically compensated for in all patients. Late Complications The overall freedom from late complications is shown in Figure 5. At 3 years, 84.5% of the patients in the MVR group, 8.2% in the AVR group, and 78.4% in the DVR group were free from late complications. Comment The B-S M prosthesis was introduced in 982 in an effort to overcome the strut fracture problem associated with some of the previous Bjork-Shiley models. Another object of the design change was to diminish the resistance to forward flow and to reduce turbulence beyond the valve. These aims were achieved by letting the convexoconcave disk open to 7 degrees and by increasing the relative size of the smaller orifice [6]. Aris and co-workers [7] have recently described the Table 3. Blood Data Collected fro& 295 Patients Suroiving Beyond 3 Days Postoperation AVR MVR DVR Variable Preop. < yr > yr Preop. < yr > yr Preop. < yr > yr Hemoglobin (@d; normal, 3.- (N = 28) (N = 75) (N = 6) (N = 3) (N = 72) (N = 79) (N = 36) (N = 7) (N = 9) 6.3 gddl) keticulocytes (%; normal,.2- (N = 27) (N = 7) (N = ) (N = 28) (N = 64) (N = 73) (N = 6) (N = 9) (N = 2).5%) LDH (% of upper normal; normal, (N = 77) (N = 75) (N = 2) (N = 29) (N = 69) (N = 79) (N = 39) (N = 23) (N = 2) <loo) Haptoglobin (mg/ml; normal, (N = 44) (N = 64) (N = 9) (N = 3) (N = 6) (N = 58) (N = 9) (N = 5) (N = 6).3-.8 mg/ml) = aortic valve replacement; MVR = mitral valve replacement; DVR = double-valve replacement; LDH = lactic dehydrogenase.
6 69 Thulin et al: Replacement with Bjork-Shiley Monostrut Valve ' t I I I AVR MVR DVR Time after surgery (months) Fig 5. Actuarial incidence of event-free survival after heart valve replacement with Bjork-Shiley Monostrut prostheses. (MVR = mitral valve replacement; AVR = aortic valve replacement; DVR = doublevalve replacement.) hemodynamic function of the B-S M valve in the aortic position. These authors found a mean resting systolic pressure gradient across the prosthesis of 2.7 * 6.3 mm Hg, which did not increase during exercise. Five patients with a 2-mm prosthesis had a gradient of 5.5 * 8. mm Hg at rest. The main purpose of the present investigation was to study the clinical performance of the B-S M, particularly with regard to durability, thromboembolism, and prosthesis-related hemolysis. Follow-up was based on hospital visits at 9- to 2-month intervals. This method of active follow-up together with a rather wide definition of TEs probably results in a higher incidence of thromboembolic complications compared with other studies of similar kind. In the total sample of 486 patients, with 537 prostheses implanted and observed from 6 months to 4 years, there was no instance of mechanical valve failure. Further information concerning durability can be gained from a survey conducted in Europe in April, 985, by one of the authors (C. L..). A questionnaire was sent to 6 European surgeons who were known to have used the valve. Eight surgeons (7.5%) did not want to participate, and 6 (5.7%) did not answer. Thus, 92 surgeons (86.8%) responded. The survey involved 5,666 prostheses; 3,9 were used for AVR, 2,569 were used for MVR, 5 were used for tricuspid valve replacement, and was used for pulmonic valve replacement. Thrombosis occurred in three implants (.6%; 2 AVR, MVR). In none of the approximately 5, patients observed for up to 3 years had structure valve failure been documented. Although the follow-up is short, it supports the impression that the B-S M valve is a durable prosthesis with a low incidence of thrombosis. Evaluation of the incidence of thromboembolic complications was somewhat hampered by the inclusion of the early series of AVRs from the Karolinska Hospital, in which 33 of the patients were discharged without receiving anticoagulants [3]. In this group there was case of fatal valve thrombosis and 3 cases of systemic emboli. A second case of fatal valve thrombosis occurred in a patient who stopped taking anticoagulants against the advice of the investigator. If these cases are excluded, however, no valve thrombosis occurred in the anticoagulated patients and the thromboembolic complication rate was equal to that reported for other comparable series of B-S convexoconcave valves [8]. The low rate of valve thrombosis with the B-S M prosthesis was further substantiated by the previously Table 4. Data from the Literature on Prosthesis-lnduced Hemolysis AVR Variable Preop. Postop. Percent Increase Preop. Postop. Percent Increase Bjork-Shiley standard prosthesis LDH (% of upper normal) No. of patients Starr-Edwards prosthesis LDH (% of upper normal) No. of patients Lillehei-Kaster prosthesis LDH (% of upper normal) No. of patients St. Jude prosthesis LDH (% of upper normal) No. of patients 4 73 Bjork-Shiley Monostrut prosthesis (present series) LDH (% of upper normal) No. of pabents AVR = aortic valve replacement; MVR = mitral valve replacement; LDH = lactic dehydrogenase Source: Adapted from Horstkotte et a [ll]. MVR
7 7 The Annals of Thoracic Surgery Vol 45 No 2 February 988 mentioned European survey. We have chosen to use a rather broad definition of TEs, including TIAs and amaurosis fugax, and we believe that this has given us a truer figure for the overall incidence of TEs [9,. With the exception of the 2 patients with valve thrombosis caused by the absence of anticoagulation, there were no fatal TEs. Only a few of the patients had permanent sequelae. In the present study, there was no statistical correlation between the incidence of embolism and such variables as valve location, atrial fibrillation, history of preoperative embolism, and patient age. Furthermore, there was no correlation between embolism and the type of suture ring used. Disk interference was observed in 2 patients after MVR. Both patients were women with mitral stenosis, and both received large prostheses (29 and 3 mm, respectively). It is possible that too large a prosthesis was chosen in relation to left ventricular size in these 2 patients. One patient was reoperated on twice, with reorientation of the disk. In addition, she was reoperated on twice because of bleeding, and she ultimately died of complications from the many operations and blood transfusions. The other patient was reoperated on once, with reorientation of the valve; thereafter, valve function was normal and she recovered from the operation. Interestingly, a minor degree of disk impingement reappeared six months postoperatively and disappeared again one year later when sinus rhythm returned, offering better ventricular filling. The degree of mechanical hemolysis in the absence of periprosthetic leakage was low with the B-S M prosthesis. Compared with similar data from other types of valve prosthesis, the Bjork-Shiley valve prostheses including the B-S M valve appear to have a lower degree of mechanical hemolysis (Table 4) [9]. Hemolysis was compensated for by a slight increase in red blood cell production. This result means that DVR or even triple-valve replacement can be performed safely with this prosthesis. Although longer follow-up will be required to obtain definitive data, our observations suggest that the B-S M valve represents an improvement over the previous Bjork-Shiley models, particularly with regard to durability. References. Bjork VO: A new tilting disc valve prosthesis. Scand J Thorac Cardiovasc Surg 3:, Bjork VO, Lindblom D: The Monostrut Bjork-Shiley heart valve. J Am Coll Cardiol 6:42, Lindblom D, Lindblom U, Henze A, et al: Three-year clinical results with the Bjork-Shiley Monostrut prosthesis. J Thorac Cardiovasc Surg 94:34, Lee ET: Statistical Methods for Survival Data Analysis. Belmont, CA, Lifetime Learning Publications, Helwig I, Council K (eds): SAS User s Guide. Raleigh, NC, SAS Institute, Bjork VO: The optimal opening angle of the Bjork-Shiley tilting disc valve prosthesis. Scand J Thorac Cardiovasc Surg 5:223, Aris A, Crexells C, Auge JM, et al: Hernodynamic evaluation of the integral Monostrut Bjork-Shiley prosthesis in aortic position. Ann Thorac Surg 4234, Sethia B, Turner MA, Lewis S, et al: Fourteen years experience with the Bjork-Shiley tilting disc prosthesis. J Thorac Cardiovasc Surg 9:35, McGoon DC: The risk of thromboembolism following valvular operations: how does one know? J Thorac Cardiovasc Surg 88782, 984. Edmunds LH: Thromboembolic complications of current cardiac valvular prostheses. Ann Thorac Surg 34:96, 982. Horstkotte D, Aul C, Seipel L, et al: Influence of valve type and valve function on chronic intravascular hemolysis following mitral and aortic replacement using alloprostheses. Z Kardiol 72:57, 983
16 YEAR RESULTS Carpentier-Edwards PERIMOUNT Mitral Pericardial Bioprosthesis, Model 6900
CLINICAL COMMUNIQUé 6 YEAR RESULTS Carpentier-Edwards PERIMOUNT Mitral Pericardial Bioprosthesis, Model 69 The Carpentier-Edwards PERIMOUNT Mitral Pericardial Valve, Model 69, was introduced into clinical
More informationLong-term Experience with the Bjork-Shiley Monostrut Tilting Disc Valve
J Korean Med Sci 2007; 22: 1060-4 ISSN 1011-8934 DOI: 10.3346/jkms.2007.22.6.1060 Copyright The Korean Academy of Medical Sciences Long-term Experience with the Bjork-Shiley Monostrut Tilting Disc Valve
More informationCLINICAL COMMUNIQUE 16 YEAR RESULTS
CLINICAL COMMUNIQUE 6 YEAR RESULTS Carpentier-Edwards PERIMOUNT Mitral Pericardial Bioprosthesis, Model 6900 Introduction The Carpentier-Edwards PERIMOUNT Mitral Pericardial Valve, Model 6900, was introduced
More information42yr Old Male with Severe AR Mild LV dysfunction s/p TOF -AV Replacement(tissue valve) or AoV plasty- Kyung-Hwan Kim
42yr Old Male with Severe AR Mild LV dysfunction s/p TOF -AV Replacement(tissue valve) or AoV plasty- Kyung-Hwan Kim Current Guideline for AR s/p TOF Surgery is reasonable in adults with prior repair of
More informationClinical material and methods. Copyright by ICR Publishers 2003
Fourteen Years Experience with the CarboMedics Valve in Young Adults with Aortic Valve Disease Jan Aagaard 1, Jens Tingleff 2, Per V. Andersen 1, Christel N. Hansen 2 1 Department of Cardio-Thoracic and
More informationHeart valve replacement with the Bjork-Shiley and St Jude Medical prostheses: A randomized comparison in 178 patients
European Heart Journal (1990) 11, 583-591 Heart valve replacement with the Bjork-Shiley and St Jude Medical prostheses: A randomized comparison in 178 patients S. VOGT, A. HOFFMANN, J. ROTH, P. DUBACH,
More informationP have been used for mitral and aortic valve replacement
A -Year Comparison of Mitral Valve Replacement With Carpentier-Edwards and Hancock Porcine Bioprostheses P. Perier, MD, A. Deloche, MD, S. Chauvaud, MD, J. C. Chachques, MD, J. Relland, MD, J. N. Fabiani,
More informationTen-Year Follow-up in Aortic Valve Replacement Using the Bjork-Shiley Prosthesis
Ten-Year Follow-up in Aortic Valve Replacement Using the Bjork-Shiley Prosthesis David Cheung, M.D., Robert J. Flemma, M.D., Donald C. Mullen, M.D., Denvard Lepley, Jr., M.D., Alfred J. Anderson, M.S.,
More informationClinical Evaluation of the Lillehei-Kaster Pivoting-Disc Valve
Clinical Evaluation of the Lillehei-Kaster Pivoting-Disc Valve Peter J. K. Starek, M.D., Lambert P. McLaurin, M.D., Benson R. Wilcox, M.D., and Gordon F. Murray, M.D. ABSTRACT A four-year clinical evaluation
More informationSmeloff-Cutter Prosthesis: 1- to 12-Year Follow-up David S. Starr, M.D., Gerald M. Lawrie, M.D., J. F. Howell, M.D., and George C. Morris, Jr., M.D.
Clinical Experience with the Smeloff-Cutter Prosthesis: 1- to 12-Year Follow-up David S. Starr, M.D., Gerald M. Lawrie, M.D., J. F. Howell, M.D., and George C. Morris, Jr., M.D. ABSTRACT To determine the
More informationCarpentier-Edwards Pericardial Valve in the Aortic Position: 25-Years Experience
SURGERY: The Annals of Thoracic Surgery CME Program is located online at http://www.annalsthoracicsurgery.org/cme/ home. To take the CME activity related to this article, you must have either an STS member
More informationLong-Term Results With the Medtronic-Hall Valvular Prosthesis
Long-Term Results With the Medtronic-Hall Valvular Prosthesis Cary W. Akins, MD Cardiac Surgical Unit, Massachusetts General Hospital, Boston, Massachusetts Background. Although more than 170,000 Medtronic-
More informationSpotlight on valvular heart disease guidelines. Prosthetic heart valves. Bernard Iung Bichat Hospital, Paris Diderot University Paris, France
Spotlight on valvular heart disease guidelines. Prosthetic heart valves. Bernard Iung Bichat Hospital, Paris Diderot University Paris, France Faculty disclosure First name - last name I disclose the following
More informationW e have previously reported the results of a randomised
715 CARDIOVASCULAR MEDICINE Twenty year comparison of a mechanical heart valve with porcine bioprostheses H Oxenham, P Bloomfield, D J Wheatley, R J Lee, J Cunningham, R J Prescott, H C Miller... See end
More informationLate Stenosis of Starr-Edwards Cloth-Covered Prostheses
Late Stenosis of Starr-Edwards Cloth-Covered Prostheses Walter Smithwick, 111, M.D., Nicholas T. Kouchoukos, M.D., Robert B. Karp, M.D., Albert D. Pacifico, M.D., and John W. Kirklin, M.D. ABSTRACT During
More informationOutcomes of Mitral Valve Repair for Mitral Regurgitation Due to Degenerative Disease
Outcomes of Mitral Valve Repair for Mitral Regurgitation Due to Degenerative Disease TIRONE E. DAVID, MD ; SEMIN THORAC CARDIOVASC SURG 19:116-120c 2007 ELSEVIER INC. PRESENTED BY INTERN 許士盟 Mitral valve
More informationDurability and Outcome of Aortic Valve Replacement With Mitral Valve Repair Versus Double Valve Replacement
Durability and Outcome of Aortic Valve Replacement With Mitral Valve Repair Versus Double Valve Replacement Masaki Hamamoto, MD, Ko Bando, MD, Junjiro Kobayashi, MD, Toshihiko Satoh, MD, MPH, Yoshikado
More informationDepartment of Cardiothoracic Surgery, Heart and Lung Center, Lund University Hospital, Lund, Sweden
Long-Term Outcome of the Mitroflow Pericardial Bioprosthesis in the Elderly after Aortic Valve Replacement Johan Sjögren, Tomas Gudbjartsson, Lars I. Thulin Department of Cardiothoracic Surgery, Heart
More informationLong-term results (22 years) of the Ross Operation a single institutional experience
Long-term results (22 years) of the Ross Operation a single institutional experience Authors: Costa FDA, Schnorr GM, Veloso M,Calixto A, Colatusso D, Balbi EM, Torres R, Ferreira ADA, Colatusso C Department
More informationSURGICAL ABLATION OF ATRIAL FIBRILLATION DURING MITRAL VALVE SURGERY THE CARDIOTHORACIC SURGICAL TRIALS NETWORK
SURGICAL ABLATION OF ATRIAL FIBRILLATION DURING MITRAL VALVE SURGERY THE CARDIOTHORACIC SURGICAL TRIALS NETWORK Marc Gillinov, M.D. For the CTSN Investigators ACC Late Breaking Clinical Trials March 16,
More informationAspirin or Coumadin as the Drug of Choice
Aspirin or Coumadin as the Drug of Choice for Valve Replacement with Porcine Bioprosthesis L. Nufiez, M.D., M. Gil Aguado, M.D., D. Celemin, M.D., A. Iglesias, M.D., and J. L. Larrea, M.D. ABSTRACT Eight
More informationBall Valve (Smeloff-Cutter) Aortic Valve Replacement Without Anticoagulation
Ball Valve (Smeloff-Cutter) Aortic Valve Replacement Without Anticoagulation Begonia Gometza, MD, and Carlos M. G. Duran, MD, PhD Department of Cardiovascular Diseases, King Faisal Specialist Hospital
More informationKinsing Ko, Thom de Kroon, Najim Kaoui, Bart van Putte, Nabil Saouti. St. Antonius Hospital, Nieuwegein, The Netherlands
Minimal Invasive Mitral Valve Surgery After Previous Sternotomy Without Aortic Clamping: Short- and Long Term Results of a Single Surgeon Single Institution Kinsing Ko, Thom de Kroon, Najim Kaoui, Bart
More informationUpdate on Oral Anticoagulation for Mechanical Heart Valves
Update on Oral Anticoagulation for Mechanical Heart Valves Douglas C. Anderson, Pharm.D., D.Ph. Professor and Chair Dept. of Pharmacy Practice Cedarville University School of Pharmacy OHIO SOCIETY OF HEALTH-SYSTEM
More informationA Surgeon s Perspective Guidelines for the Management of Patients with Valvular Heart Disease Adapted from the 2006 ACC/AHA Guideline Revision
A Surgeon s Perspective Guidelines for the Management of Patients with Valvular Heart Disease Adapted from the 2006 ACC/AHA Guideline Revision Prof. Pino Fundarò, MD Niguarda Hospital Milan, Italy Introduction
More information2017 Cardiovascular Symposium CARDIAC SURGERY UPDATE: SMALLER INCISIONS AND LESS COUMADIN DAVID L. SAINT, MD
2017 Cardiovascular Symposium CARDIAC SURGERY UPDATE: SMALLER INCISIONS AND LESS COUMADIN DAVID L. SAINT, MD David L Saint M.D. Tallahassee Memorial Hospital Southern Medical Group Division of Cardiothoracic
More informationThe CarboMedics bileaflet prosthetic heart was introduced
The CarboMedics Valve: Experience With 1,049 Implants José M. Bernal, MD, José M. Rabasa, MD, Francisco Gutierrez-Garcia, MD, Carlos Morales, MD, J. Francisco Nistal, MD, and José M. Revuelta, MD Department
More informationIndication, Timing, Assessment and Update on TAVI
Indication, Timing, Assessment and Update on TAVI Swedish Heart and Vascular Institute Ming Zhang MD PhD Interventional Cardiology Structure Heart Disease Conflict of Interest None Starr- Edwards Mechanical
More informationThe St. Jude Medical Biocor Bioprosthesis
The St. Jude Medical Biocor Bioprosthesis Clinical Evidence of Long-term Durability Long-term Biocor Experience A Review and Comparative Assessment Long-term Biocor Stented Tissue Valve Studies Twenty-year
More informationTSDA Boot Camp September 13-16, Introduction to Aortic Valve Surgery. George L. Hicks, Jr., MD
TSDA Boot Camp September 13-16, 2018 Introduction to Aortic Valve Surgery George L. Hicks, Jr., MD Aortic Valve Pathology and Treatment Valvular Aortic Stenosis in Adults Average Course (Post mortem data)
More informationIntensity of oral anticoagulation after implantation of St. Jude Medical mitral or multiple valve replacement: lessons learned from GELIA (GELIA 5)
European Heart Journal Supplements () 3 (Supplement Q), Q39 Q43 Intensity of oral anticoagulation after implantation of St. Jude Medical mitral or multiple valve replacement: lessons learned from GELIA
More informationDoes Patient-Prosthesis Mismatch Affect Long-term Results after Mitral Valve Replacement?
Original Article Does Patient-Prosthesis Mismatch Affect Long-term Results after Mitral Valve Replacement? Hiroaki Sakamoto, MD, PhD, and Yasunori Watanabe, MD, PhD Background: Recently, some articles
More informationSurgical AVR: Are there any contraindications? Pyowon Park Samsung Medical Center Seoul, Korea
Surgical AVR: Are there any contraindications? Pyowon Park Samsung Medical Center Seoul, Korea Contents Decision making in surgical AVR in old age Clinical results of AVR with tissue valve Impact of 19mm
More informationThe risk-benefit ratio of mitral valve operation is
Degenerative Mitral Regurgitation: When Should We Operate? Malcolm J. R. Dalrymple-Hay, PhD, Mark Bryant, Richard A. Jones, MRCP, Stephen M. Langley, FRCS, Steven A. Livesey, FRCS, and James L. Monro,
More informationEchocardiographic Evaluation of Mitral Valve Prostheses
Echocardiographic Evaluation of Mitral Valve Prostheses Dennis A. Tighe, M.D., FACC, FACP, FASE Cardiovascular Medicine University of Massachusetts Medical School Worcester, MA www.asecho.org 1 Nishimura
More informationT sors in the following aspects: the porcine aortic valve
Clinical and Hemodynamic Assessment of the Hancock I1 Bioprosthesis Tirone E. David, MD, Susan Armstrong, MSc, and Zhao Sun, MA Division of Cardiovascular Surgery, The Toronto Hospital and University of
More informationEffect of Valve Suture Technique on Incidence of Paraprosthetic Regurgitation and 10-Year Survival
Effect of Valve Suture Technique on Incidence of Paraprosthetic Regurgitation and 10-Year Survival Sukumaran K. Nair, FRCS (C Th), Gauraang Bhatnagar, MBBS, Oswaldo Valencia, MD, and Venkatachalam Chandrasekaran,
More informationBicuspid aortic root spared during ascending aorta surgery: an update of long-term results
Short Communication Bicuspid aortic root spared during ascending aorta surgery: an update of long-term results Marco Russo, Guglielmo Saitto, Paolo Nardi, Fabio Bertoldo, Carlo Bassano, Antonio Scafuri,
More informationAortic Valve Replacement with Starr-Edwards Valves over 14 Years
Aortic Valve Replacement with Starr-Edwards Valves over 4 Years W. H. Wain, B.Sc., Ph.D., P. J. Drury, B.Sc., Ph.D., andd. N. Ross, F.R.C.S. ABSTRACT Three hundred thirteen patients underwent aortic valve
More informationThe operative mortality rate after redo valvular operations
Clinical Outcomes of Redo Valvular Operations: A 20-Year Experience Naoto Fukunaga, MD, Yukikatsu Okada, MD, Yasunobu Konishi, MD, Takashi Murashita, MD, Mitsuru Yuzaki, MD, Yu Shomura, MD, Hiroshi Fujiwara,
More informationCONTRIBUTION. Aortic valve replacement in young patients: long-term follow-up
CONTRIBUTION Aortic valve replacement in young patients: long-term follow-up DOUGLAS S. MOODIE, MD; USAMA HANHAN, MD; RICHARD STERBA, MD; DANIEL J. MURPHY, Jr, MD; ELIOT R. ROSENKRANZ, MD; ANDREA M. KOVACS,
More informationClinical event rates with the On-X bileaflet mechanical heart valve: A multicenter experience with follow-up to 12 years
Clinical event rates with the On-X bileaflet mechanical heart valve: A multicenter experience with follow-up to 12 years John B. Chambers, MD, FRCP, FACC, a Jose L. Pomar, MD, PhD, FETCS, b Carlos A. Mestres,
More informationLONG-TERM RESULTS OF HEART VALVE REPLACEMENT WITH THE EDWARDS DUROMEDICS BILEAFLET PROSTHESIS: A PROSPECTIVE TEN-YEAR CLINICAL FOLLOW-UP
LONG-TERM RESULTS OF HEART VALVE REPLACEMENT WITH THE EDWARDS DUROMEDICS BILEAFLET PROSTHESIS: A PROSPECTIVE TEN-YEAR CLINICAL FOLLOW-UP Bruno K. Podesser, MD a Gudrun Khuenl-Brady, MD a Ernst Eigenbauer,
More informationExperience with 500 Stentless Aortic Valve Replacements
Experience with 500 Stentless Aortic Valve Replacements Dimitrios C. Iliopoulos, MD Cardiac Surgeon Ass. Professor of Surgery University of Athens, School of Medicine I declare no conflict of interest
More informationReconstruction of the intervalvular fibrous body during aortic and
Aortic and mitral valve replacement with reconstruction of the intervalvular fibrous body: An analysis of clinical outcomes Nilto C. De Oliveira, MD Tirone E. David, MD Susan Armstrong, MSc Joan Ivanov,
More informationA valve was initiated at the Medical University of
St. Jude Prosthesis for Aortic and Mitral Valve Replacement: A Ten-Year Experience John M. Kratz, MD, Fred A. Crawford, Jr, MD, Robert M. Sade, MD, Arthur J. Crumbley, MD, and Martha R. Stroud, MS Division
More informationMedtronic Mosaic porcine bioprosthesis: Assessment of 12-year performance
Medtronic Mosaic porcine bioprosthesis: Assessment of 12-year performance W. R. Eric Jamieson, MD, a Friedrich-Christian Riess, MD, b Peter J. Raudkivi, MD, c Jacques Metras, MD, d Edward F. G. Busse,
More informationORIGINAL PAPER. The long-term results and changing patterns of biological valves at the mitral position in contemporary practice in Japan
Nagoya J. Med. Sci. 78. 369 ~ 376, 2016 doi:10.18999/nagjms.78.4.369 ORIGINAL PAPER The long-term results and changing patterns of biological valves at the mitral position in contemporary practice in Japan
More informationMitral Valve Repair Versus Replacement in Simultaneous Mitral and Aortic Valve Surgery for Rheumatic Disease
Mitral Valve Repair Versus Replacement in Simultaneous Mitral and Aortic Valve Surgery for Rheumatic Disease Kenji Kuwaki, MD, PhD, Nobuyoshi Kawaharada, MD, PhD, Kiyofumi Morishita, MD, PhD, Tetsuya Koyanagi,
More informationNineteen-Millimeter Aortic St. Jude Medical Heart Valve Prosthesis: Up to Sixteen Years Follow-up
Nineteen-Millimeter Aortic St. Jude Medical Heart Valve Prosthesis: Up to Sixteen Years Follow-up Dilip Sawant, FRCS, Arun K. Singh, MD, William C. Feng, MD, Arthur A. Bert, MD, and Fred Rotenberg, MD
More informationThe Medtronic-Hall Cardiac Valve:
The Medtronic-Hall Cardiac Valve: 7?h Years' Clinical Experience Regent L. Beaudet, M.D., Normand L. Poirier, M.D., Daniel Doyle, M.D., Gisde Nakhlb, M.Sc., and Christiane Gauvin, M.T. ABSTRACT Clinical
More informationAlthough mitral valve replacement (MVR) is no longer the surgical
Surgery for Acquired Cardiovascular Disease Ruel et al Late incidence and predictors of persistent or recurrent heart failure in patients with mitral prosthetic valves Marc Ruel, MD, MPH a,b Fraser D.
More informationHani K. Najm MD, Msc, FRCSC, FRCS (Glasgow), FACC, FESC President of Saudi Heart Association King Abdulaziz Cardiac Centre Riyadh, Saudi Arabia.
Hani K. Najm MD, Msc, FRCSC, FRCS (Glasgow), FACC, FESC President of Saudi Heart Association King Abdulaziz Cardiac Centre Riyadh, Saudi Arabia. Decision process for Management of any valve Timing Feasibility
More information15-Year Comparison of Supra-Annular Porcine and PERIMOUNT Aortic Bioprostheses
ORIGINAL CONTRIBUTION 15-Year Comparison of Supra-Annular Porcine and PERIMOUNT Aortic Bioprostheses WR Eric Jamieson, MD, Eva Germann, MSc, Michel R Aupart, MD 1, Paul H Neville, MD 1, Michel A Marchand,
More informationHani K. Najm MD, Msc, FRCSC FACC, FESC President Saudi Society for Cardiac Surgeons Associate Professor of Cardiothoracic Surgery King Abdulaziz
Hani K. Najm MD, Msc, FRCSC FACC, FESC President Saudi Society for Cardiac Surgeons Associate Professor of Cardiothoracic Surgery King Abdulaziz Cardiac Centre Riyadh, Saudi Arabia Decision process for
More informationA prospective evaluation of the Bjbrk-Shiley, Hancock, and Carpentier-Edwards heart valve prostheses
THERAPY AND PREVENTION VALVE REPLACEMENT A prospective evaluation of the Bjbrk-Shiley, Hancock, and Carpentier-Edwards heart valve prostheses PETER BLOOMFIELD, M.R.C.P., ARTHUR H. KITCHIN, F.R.C.P.. DAVID
More informationResults of Mitral Valve Replacement, with Special Reference to the Functional Tricuspid Insufficiency
Results of Mitral Valve Replacement, with Special Reference to the Functional Tricuspid Insufficiency Ken-ichi ASANO, M.D., Masahiko WASHIO, M.D., and Shoji EGUCHI, M.D. SUMMARY (1) Surgical results of
More informationProf. Patrizio LANCELLOTTI, MD, PhD Heart Valve Clinic, University of Liège, CHU Sart Tilman, Liège, BELGIUM
The Patient with Aortic Stenosis and Mitral Regurgitation Prof. Patrizio LANCELLOTTI, MD, PhD Heart Valve Clinic, University of Liège, CHU Sart Tilman, Liège, BELGIUM Aortic Stenosis + Mitral Regurgitation?
More informationThe CarboMedics prosthetic valve (Sulzer CarboMedics,
Long-Term Result of 1144 CarboMedics Mechanical Valve Implantations Chang Hyun Kang, MD, Hyuk Ahn, MD, Kyung Hwan Kim, MD, and Ki-Bong Kim, MD Department of Thoracic and Cardiovascular Surgery, Seoul National
More informationIschemic mitral valve reconstruction and replacement: Comparison of long-term survival and complications
Surgery for Acquired Cardiovascular Disease Ischemic mitral valve reconstruction and replacement: Comparison of long-term survival and complications Eugene A. Grossi, MD Judith D. Goldberg, ScD Angelo
More informationValvular Heart Disease
Valvular Heart Disease B K Singh, MD, FACC Disclosures: None 1 CARDIAC CYCLE S2 S2=A2P2 S1=M1T1 S4 S1 S3 2 JVP Carotid S1 Slitting of S2 S3 S4 Ejection click Opening snap Dynamic Auscultation What is the
More informationRepair or Replacement
Surgical intervention post MitraClip Device: Repair or Replacement Saudi Heart Association, February 21-24 Rüdiger Lange, MD, PhD Nicolo Piazza, MD, FRCPC, FESC German Heart Center, Munich, Germany Division
More informationMitral Valve Disease, When to Intervene
Mitral Valve Disease, When to Intervene Swedish Heart and Vascular Institute Ming Zhang MD PhD Interventional Cardiology Structure Heart Disease Conflict of Interest None Current ACC/AHA guideline Stages
More informationand Coronary Artery Surgery George M. Callard, M.D., John B. Flege, Jr., M.D., and Joseph C. Todd, M.D.
Combined Valvular and Coronary Artery Surgery George M. Callard, M.D., John B. Flege, Jr., M.D., and Joseph C. Todd, M.D. ABSTRACT Between July, 97, and March, 975,45 patients underwent combined valvular
More informationThe Bjork-Shiley Prosthesis
The Bjork-Shiley Prosthesis A Significant Advance in Aortic Valve Replacement Javier Fernandez, M.D., Vladir Maranhao, M.D., Alden S. Gooch, M.D., Dryden Morse, M.D., and Henry T. Nichols, M.D." ABSTRACT
More informationPROSTHETIC VALVE BOARD REVIEW
PROSTHETIC VALVE BOARD REVIEW The correct answer D This two chamber view shows a porcine mitral prosthesis with the typical appearance of the struts although the leaflets are not well seen. The valve
More informationThe Ross Procedure: Outcomes at 20 Years
The Ross Procedure: Outcomes at 20 Years Tirone David Carolyn David Anna Woo Cedric Manlhiot University of Toronto Conflict of Interest None The Ross Procedure 1990 to 2004 212 patients: 66% 34% Mean age:
More informationEcho Evaluation of a Mitral Valve Prostheses Sunday, February 14, :50 2:10 PM 20 min
2016 ASE State of the Art Echocardiography Course Tucson, AZ Echo Evaluation of a Mitral Valve Prostheses Sunday, February 14, 2016 1:50 2:10 PM 20 min 1 M U H A M E D S A R I Ć, M D, P H D D i r e c t
More informationTHE IMPACT OF AGE, CORONARY ARTERY DISEASE, AND CARDIAC COMORBIDITY ON LATE SURVIVAL AFTER BIOPROSTHETIC AORTIC VALVE REPLACEMENT
THE IMPACT OF AGE, CORONARY ARTERY DISEASE, AND CARDIAC COMORBIDITY ON LATE SURVIVAL AFTER BIOPROSTHETIC AORTIC VALVE REPLACEMENT Gideon Cohen, MD Tirone E. David, MD Joan Ivanov, MSc Sue Armstrong, MSc
More informationW. Schlick, M.D., J. Mlczoch, M.D., G. Kronik, M.D., and E. Wolner, M.D.
Implantation of the Durornedics Bileaflet Cardiac Valve Prosthesis in 400 Patients W. Klepetko, M.D., A. Moritz, M.D., G. KhunlBrady, M.D., W. Schreiner, Ph.D., W. Schlick, M.D., J. Mlczoch, M.D., G. Kronik,
More informationTAVR 2018: TAVR has high clinical efficacy according to baseline patient risk! ii. Con
TAVR 2018: TAVR has high clinical efficacy according to baseline patient risk! ii. Con Dimitrios C. Angouras, MD, FETCS Associate Professor of Cardiac Surgery National and Kapodistrian University of Athens,
More informationHeart Valves: Before and after surgery
Heart Valves: Before and after surgery Tim Sutton, Consultant Cardiologist Middlemore Hospital, Auckland Auckland Heart Group Indications for intervention in Valvular disease To prevent sudden death and
More informationTwenty-year experience with the St Jude Medical mechanical valve prosthesis
Surgery for Acquired Cardiovascular Disease Ikonomidis et al Twenty-year experience with the St Jude Medical mechanical valve prosthesis John S. Ikonomidis, MD, PhD John M. Kratz, MD Arthur J. Crumbley
More informationAutologous Pulmonary Valve Replacement of the Diseased Aortic Valve
Autologous Pulmonary Valve Replacement of the Diseased Aortic Valve By L. GONZALEZ-LAvIN, M.D., M. GEENS. M.D., J. SOMERVILLE, M.D., M.R.C.P., ANm D. N. Ross, M.B., CH.B., F.R.C.S. SUMMARY Living tissue
More informationResults of Aortic Valve Preservation and Repair
Results of Aortic Valve Preservation and Repair Department of Cardiothoracic and Vascular Surgery Cliniques Universitaires St. Luc Brussels, Belgium Gebrine Elkhoury Institutional experience in AV preservation
More informationSupplementary Online Content
Supplementary Online Content Inohara T, Manandhar P, Kosinski A, et al. Association of renin-angiotensin inhibitor treatment with mortality and heart failure readmission in patients with transcatheter
More informationSREE CHITRA TIRUNAL INSTITUTE FOR MEDICAL SCIENCES AND TECHNOLOGY THIRUVANANTHAPURAM, KERALA, INDIA
SREE CHITRA TIRUNAL INSTITUTE FOR MEDICAL SCIENCES AND TECHNOLOGY THIRUVANANTHAPURAM, KERALA, INDIA - 695011 St. Jude Medical versus TTK Chitra mechanical heart valves at aortic/mitral postion Comparison
More informationControversy exists regarding which valve type is best
Treatment of Endocarditis With Valve Replacement: The Question of Tissue Versus Mechanical Prosthesis Marc R. Moon, MD, D. Craig Miller, MD, Kathleen A. Moore, BS, Phillip E. Oyer, MD, PhD, R. Scott Mitchell,
More informationMitral Valve Redacernent with the Modified Univekity of Cape Town (UCT) Prosthesis: Clinical and Hernodynamic Results
Mitral Valve Redacernent with the Modified Univekity of Cape Town (UCT) Prosthesis: Clinical and Hernodynamic Results F. Henry Ellis, Jr., M.D., Ph.D., Robert W. Healy, M.D., and Sidney Alexander, M.D.
More informationHemodynamics and Early Clinical Performance of the St. Jude Medical Regent Mechanical Aortic Valve
Hemodynamics and Early Clinical Performance of the St. Jude Medical Regent Mechanical Aortic Valve David S. Bach, MD, Marc P. Sakwa, MD, Martin Goldbach, MD, Michael R. Petracek, MD, Robert W. Emery, MD,
More informationRESEARCH AND REVIEWS: JOURNAL OF PHARMACOLOGY AND TOXICOLOGICAL STUDIES
e-issn:2322-0139 RESEARCH AND REVIEWS: JOURNAL OF PHARMACOLOGY AND TOXICOLOGICAL STUDIES Comparative Evaluation of Safety Outcomes of Different Prosthetic Valves in Indian Subjects. Kama Raval 1 *, Reena
More informationFocused. se with 2008 F. lar Heart Diseas. date. ents With Valvul. Upd. gement of Patie. lines for Manag. HA 2006 Guidel ACC/AH. Fig.
ACC/AH HA 2006 Guidel nic severe AI (Fig. 4). ned by age, ay also be helpful nd echo. For AI, ollow up may be or MRI rather than mension; SD, end lines for Manag gement of Patie Upd ents With Valvul date
More informationProfessor and Chief, Division of Cardiac Surgery Chief Medical Officer, Harpoon Medical. The Houston Aortic Symposium February 23-25, 2017
James S. Gammie, MD Professor and Chief, Division of Cardiac Surgery Chief Medical Officer, Harpoon Medical The Houston Aortic Symposium February 2-25, 2017 Disclosure Statement of Financial Interest Within
More informationEmergency Intraoperative Echocardiography
Emergency Intraoperative Echocardiography Justiaan Swanevelder Department of Anaesthesia, Glenfield Hospital University Hospitals of Leicester NHS Trust, UK Carl Gustav Jung (1875-1961) Your vision will
More informationAORTIC VALVE REPLACEMENT WITH FREEHAND AUTOLOGOUS PERICARDIUM
AORTIC VALVE REPLACEMENT WITH FREEHAND AUTOLOGOUS PERICARDIUM Fifty-one patients with a mean age of 31.2 years underwent aortic valve replacement with glutaraldehyde-treated autologous pericardium. Pure
More informationin Patients Having Aortic Valve Replacement John T. Santinga, M.D., Marvin M. Kirsh, M.D., Jairus D. Flora, Jr., Ph.D., and James F. Brymer, M.D.
Factors Relating to Late Sudden Death in Patients Having Aortic Valve Replacement John T. Santinga, M.D., Marvin M. Kirsh, M.D., Jairus D. Flora, Jr., Ph.D., and James F. Brymer, M.D. ABSTRACT The preoperative
More informationOpen-Heart Surgery in Patients More than 65 Years Old
Open-Heart Surgery in Patients More than 65 Years Old Donald A. Barnhorst, M.D., Emilio R. Giuliani, M.D., James R. Pluth, M.D., Gordon K. Danielson, M.D., Robert B. Wallace, M.D., and Dwight C. McGoon,
More informationUniversity of Florida Department of Surgery. CardioThoracic Surgery VA Learning Objectives
University of Florida Department of Surgery CardioThoracic Surgery VA Learning Objectives This service performs coronary revascularization, valve replacement and lung cancer resections. There are 2 faculty
More informationAdult Cardiac Surgery
Adult Cardiac Surgery Mahmoud ABU-ABEELEH Associate Professor Department of Surgery Division of Cardiothoracic Surgery School of Medicine University Of Jordan Adult Cardiac Surgery: Ischemic Heart Disease
More informationThe ATS Medical Open Pivot heart valve (ATS Medical, 10-Year Experience With the ATS Mechanical Valve in the Mitral Position
10-Year Experience With the ATS Mechanical Valve in the Mitral Position Constantin Stefanidis, MD, Albert M. Nana, MD, Didier De Cannière, MD, PhD, Martine Antoine, MD, Jean-Luc Jansens, MD, Chi-Hoang
More informationABSTRACT Between 1961 and 1978, 6,602 valves were replaced in 5,660 patients. Reoperation for periprosthetic leakage was performed in 105 patients
Results of Reoperation for Periprosthetic Leakage Thomas A. Orszulak, M.D., Hartzell V. Schaff, M.D., Gordon K. Danielson, M.D., James R. Pluth, M.D., Francisco J. Puga, M.D., and Jeffrey M. Piehler, M.D.
More informationESC/EACTS Guidelines for the Management of Valvular Heart Disease
ES/EATS Guidelines for the Management of Valvular Heart Disease European Journal of ardio-thoracic Surgery 2012 - Why do we need new guidelines on the management of valvular disease? New evidence has been
More informationReoperation for Bioprosthetic Mitral Structural Failure: Risk Assessment
Reoperation for Bioprosthetic Mitral Structural Failure: Risk Assessment W.R.E. Jamieson, MD; L.H. Burr, MD; R.T. Miyagishima, MD; M.T. Janusz, MD; G.J. Fradet, MD; S.V. Lichtenstein, MD; H. Ling, MD Background
More informationRisks of Mitral Valve Replacement and
Risks of Mitral Valve Replacement and Mitral Valve Replacement with Coronary Artery Bypass James A. Magovern, M.D., John L. Pennock, M.D., David B. Campbell, M.D., William S. Pierce, M.D., and John A.
More informationDeath and other time-related events after valve replacement
PATHOPHYSIOLOGY AND NATURAL HISTORY VALVE REPLACEMENT Death and other time-related events after valve replacement EUGENE H. BLACKSTONE, M.D., AND JOHN W. KIRKLIN, M.D. ABSTRACT A total of 1533 patients
More informationExpanding Relevance of Aortic Valve Repair Is Earlier Operation Indicated?
Expanding Relevance of Aortic Valve Repair Is Earlier Operation Indicated? RM Suri, V Sharma, JA Dearani, HM Burkhart, RC Daly, LD Joyce, HV Schaff Division of Cardiovascular Surgery, Mayo Clinic, Rochester,
More informationEleven years experience with the Biocor stentless aortic bioprosthesis: clinical and hemodynamic follow-up with long-term relative survival rate
European Journal of Cardio-thoracic Surgery 22 (2002) 912 921 www.elsevier.com/locate/ejcts Eleven years experience with the Biocor stentless aortic bioprosthesis: clinical and hemodynamic follow-up with
More informationEight-Year Results of Aortic Root Replacement With the Freestyle Stentless Porcine Aortic Root Bioprosthesis
Eight-Year Results of Aortic Root Replacement With the Freestyle Stentless Porcine Aortic Root Bioprosthesis Neal D. Kon, MD,* Robert D. Riley, MD, Sandy M. Adair, RN, Dalane W. Kitzman, MD, and A. Robert
More informationIntra-operative Echocardiography: When to Go Back on Pump
Intra-operative Echocardiography: When to Go Back on Pump GREGORIO G. ROGELIO, MD., F.P.C.C. OUTLINE A. Indications for Intraoperative Echocardiography B. Role of Intraoperative Echocardiography C. Criteria
More informationRepeated mitral valve replacement in a patient with extensive annular calcification
CASE REPORT Open Access Repeated mitral valve replacement in a patient with extensive annular calcification Tadashi Kitamura 1,2*, Sachito Fukuda 1, Takahiro Sawada 1, Sumio Miura 1, Ikutaro Kigawa 1,3
More information